0000950170-24-045698.txt : 20240418
0000950170-24-045698.hdr.sgml : 20240418
20240418202343
ACCESSION NUMBER: 0000950170-24-045698
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240416
FILED AS OF DATE: 20240418
DATE AS OF CHANGE: 20240418
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRATES JAMES M
CENTRAL INDEX KEY: 0001235598
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 24855377
MAIL ADDRESS:
STREET 1: 88 SIDNEY ST
CITY: CAMBRIDGE
STATE: MA
ZIP: 021394136
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
ownership.xml
4
X0508
4
2024-04-16
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001235598
FRATES JAMES M
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02141
false
true
false
false
Chief Financial Officer
false
Common Stock
2024-04-16
4
A
false
91180
0.00
A
225964
D
Common Stock
15459
I
By Trust
Common Stock
11072
I
By Trust
Stock Option (right to buy)
2.01
2024-04-16
4
A
false
120000
0.00
A
2034-04-15
Common Stock
120000
120000
D
The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
/s/ Joshua B. Cohen, as Attorney in Fact
2024-04-18